Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Pieri

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Haematologica|April 5, 2015
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosisChristophe Desterke, Christophe Martinaud, Bernadette Guerton, et al.
American Journal of Hematology|June 7, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patientsPaola Guglielmelli, Giada Rotunno, Annalisa Pacilli, et al.
American Journal of Hematology|December 23, 2011
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignanciesAna Puda, Jelena D Milosevic, Tiina Berg, et al.
Blood|July 20, 2014
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisAyalew Tefferi, Paola Guglielmelli, Dirk R Larson, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Blood|January 17, 2012
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcomeTiziano Barbui, Jürgen Thiele, Francesco Passamonti, et al.
American Journal of Hematology|April 3, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupGiada Rotunno, Annalisa Pacilli, Valentina Artusi, et al.
Haematologica|February 13, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Blood|July 3, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisElisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Haematologica|April 5, 2015
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosisChristophe Desterke, Christophe Martinaud, Bernadette Guerton, et al.
American Journal of Hematology|June 7, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patientsPaola Guglielmelli, Giada Rotunno, Annalisa Pacilli, et al.
American Journal of Hematology|December 23, 2011
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignanciesAna Puda, Jelena D Milosevic, Tiina Berg, et al.
Blood|July 20, 2014
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisAyalew Tefferi, Paola Guglielmelli, Dirk R Larson, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Blood|January 17, 2012
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcomeTiziano Barbui, Jürgen Thiele, Francesco Passamonti, et al.
American Journal of Hematology|April 3, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupGiada Rotunno, Annalisa Pacilli, Valentina Artusi, et al.
Haematologica|February 13, 2008
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatmentsValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Blood|July 3, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisElisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Pageof 6